<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63806">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01962337</url>
  </required_header>
  <id_info>
    <org_study_id>FPA008-001</org_study_id>
    <secondary_id>2013-003337-15</secondary_id>
    <nct_id>NCT01962337</nct_id>
  </id_info>
  <brief_title>Phase 1 Single and Multiple Dose Study of FPA008 in Healthy Volunteers and Rheumatoid Arthritis Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double Blind, Placebo Controlled, Single and Multiple Ascending Dose Study of FPA008 in Healthy Volunteers and Subjects With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Five Prime Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Five Prime Therapeutics, Inc.</source>
  <oversight_info>
    <authority>Netherlands: Ministry of Health, Welfare and Sport</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, randomized, double-blind, placebo-controlled study designed in 3 parts to
      assess the safety, tolerability, and PK of single and multiple ascending doses of FPA008 in
      adult healthy volunteers (Parts 1 and 2) and adult subjects with active RA (Part 3).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and tolerability of FPA008 adminstered in healthy volunteers and RA subjects</measure>
    <time_frame>within 4-12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of all grade adverse events and dose limiting toxicities (DLT) during the DLT observation period and/or study treatment periods</description>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">89</enrollment>
  <condition>Healthy</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>FPA008 Single Dose- 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FPA008 Single Dose-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FPA008 Single Dose-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FPA008 Single Dose-4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FPA008 Multiple Dose-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dual Infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FPA008 Multiple Dose-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dual Infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FPA008 Multiple Dose-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dual Infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rheumatoid Arthritis Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RA Treatment Regimen 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rheumatoid Arthritis Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RA Treatment Regimen 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FPA008</intervention_name>
    <description>Infusion</description>
    <arm_group_label>FPA008 Single Dose- 1</arm_group_label>
    <arm_group_label>FPA008 Single Dose-2</arm_group_label>
    <arm_group_label>FPA008 Single Dose-3</arm_group_label>
    <arm_group_label>FPA008 Single Dose-4</arm_group_label>
    <arm_group_label>FPA008 Multiple Dose-1</arm_group_label>
    <arm_group_label>FPA008 Multiple Dose-2</arm_group_label>
    <arm_group_label>FPA008 Multiple Dose-3</arm_group_label>
    <arm_group_label>Rheumatoid Arthritis Dose 1</arm_group_label>
    <arm_group_label>Rheumatoid Arthritis Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Infusion</intervention_name>
    <arm_group_label>FPA008 Single Dose- 1</arm_group_label>
    <arm_group_label>FPA008 Single Dose-2</arm_group_label>
    <arm_group_label>FPA008 Single Dose-3</arm_group_label>
    <arm_group_label>FPA008 Single Dose-4</arm_group_label>
    <arm_group_label>FPA008 Multiple Dose-1</arm_group_label>
    <arm_group_label>FPA008 Multiple Dose-2</arm_group_label>
    <arm_group_label>FPA008 Multiple Dose-3</arm_group_label>
    <arm_group_label>Rheumatoid Arthritis Dose 1</arm_group_label>
    <arm_group_label>Rheumatoid Arthritis Dose 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Part 1 and 2:

          -  Healthy adult male and female subjects between the ages of 21-55 years inclusive.

          -  Subject must be willing to remain in the Clinical Research Unit (CRU) for a minimum
             of 72 hours after each dose.

        Part 3:

          -  RA male and female subjects between the ages of 21-70 years inclusive

          -  Evidence of active RA disease

          -  Inadequate response to biologic or non-biologic DMARDs

          -  Subjects will be required to be on background therapy with methotrexate.

        Exclusion Criteria:

        Parts 1, 2 and 3:

          -  BMI &lt;18 or &gt;32 kg/m2

          -  Clinically significant findings in physical exams and laboratory tests at screening
             and/or baseline

          -  Unwilling to abstain from alcohol for 48 hours prior to study start, during CRU
             confinement, as applicable, and for 48 hours prior to study visits.

          -  Unwilling to abstain from exercise more strenuous than walking during CRU
             confinement, as applicable, and for 48 hours prior to study visits.

        Parts 1 and 2:

          -  Use of any prescription, non-prescription, or herbal medications as well as
             supplements or vitamins within 4 weeks prior to dosing, unless approved by the
             Investigator.

          -  Smoking more than 10 cigarettes, or the equivalent, per day.

        Part 3:

          -  Current or previous history of inflammatory joint disease other than RA

          -  Evidence of extra-articular RA disease or systemic involvement

          -  Currently taking any medications other than those allowed per protocol guidelines

          -  Any surgical procedure including bone or joint surgery within 12 weeks prior to
             dosing

          -  Use of intra-articular (IA), intramuscular (IM), or IV corticosteroids for RA

          -  Neuropathies and neurovasculopathies
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dalia Moawad, MD</last_name>
    <role>Study Director</role>
    <affiliation>Five Prime Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dalia Moawad, MD</last_name>
    <phone>4153655659</phone>
    <email>dalia.moawad@fiveprime.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PRA Early Development Services</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sjoerd van Marle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 10, 2013</lastchanged_date>
  <firstreceived_date>October 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
